Decreased serum albumin predicts bleeding events in patients on antiplatelet therapy after percutaneous coronary intervention

Yosuke Tatami, Hideki Ishii, Toshijiro Aoki, Kazuhiro Harada, Kenshi Hirayama, Yohei Shibata, Takuya Sumi, Yosuke Negishi, Kazuhiro Kawashima, Ayako Kunimura, Toshiki Kawamiya, Dai Yamamoto, Susumu Suzuki, Toyoaki Murohara

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Background: Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population. Methods and Results: We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8-4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (eventfree rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027-0.39, P=0.001, for tertile 3 vs. tertile 1).

Original languageEnglish
Pages (from-to)999-1005
Number of pages7
JournalCirculation Journal
Issue number7
Publication statusPublished - 2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Decreased serum albumin predicts bleeding events in patients on antiplatelet therapy after percutaneous coronary intervention'. Together they form a unique fingerprint.

Cite this